Sudden Cardiac Death and Coronary Artery Disease —Pathophysiology and Risk Stratification  by EI-Sherif, Nabil et al.
Sudden Cardiac Death and Coronary Artery Disease
—Pathophysiology and Risk Stratiﬁcationy
Nabil El-Sherif MD, Abdullah Khan MD, Joseph Savarese MD, Gioia Turitto MD
State University of New York, Downstate Medical Center and New York harbor VA Healthcare System
Management of Sudden Cardiac Death (SCD) is undergoing a radical change in direction. It
is becoming increasingly appreciated that besides depressed left ventricular systolic function
and the conventional risk stratiﬁcation tools, new markers for plaque vulnerability, enhanced
thrombogenesis, speciﬁc genetic alterations of the autonomic nervous system, cardiac
sarcolemmal and contractile proteins, and familial clustering may better segregate patients
with atherosclerotic coronary artery disease who are at high risk for SCD from those who may
suﬀer from nonfatal ischemic events. Better understanding of pathophysiological processes,
such as postmyocardial infarction remodeling, the transition from compensated hypertrophy
to heart failure, and the increased cardiovascular risk of coronary artery disease in the
presence of diabetes or even a prediabetic state will help to improve both risk stratiﬁcation
and management. The rapidly developing ﬁelds of microchips technology and proteomics
may allow rapid and cost-eﬀective mass screening of multiple risk factors for SCD. The
ultimate goal is to identify novel methods for risk stratiﬁcation, risk modiﬁcation, and
prevention of SCD that could be applied to the general public at large.
(J Arrhythmia 2009; 25: 122–129)
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Coronary artery disease (CAD) and sudden
cardiac death (SCD) cascade (Figure 1)
The majority of SCD occurs in patients with
atherosclerotic CAD (65–85%).1) However, there is
considerable evidence that traditional markers of
CAD, such as hypertension, obesity, smoking,
diabetes, and lipid abnormalities, are not speciﬁc
enough to identify patients at high risk for SCD.2)
Patients with similar risk factors for CAD may suﬀer
from SCD or nonfatal ischemic events. The reason
for this diﬀerence is not clear. Exciting evidence has
been made in recent years in genetic studies of CAD
and MI. One disease-causing gene for CAD and MI
has been identiﬁed as MEF2A, which is located on
chromosome 15q26.3 and encodes for a transcrip-
tional factor with high level of expression in
coronary endothelium.3) Approximately 1% to 2%
of CAD patients may carry an MEF2A mutation.
Several other susceptibility genes have been identi-
ﬁed using genome-wide association studies or
genome-wide linkage studies.3) There is a new
understanding of the cascade that relates the distal
events of atherosclerosis to the proximal event of
SCD. New risk markers for SCD in CAD are likely
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to cluster under factors that may directly facilitate
the development of acute coronary syndromes,
speciﬁcally those factors that may facilitate transient
triggering events, including plaque rupture, en-
hanced thrombogenesis, and coronary artery
spasm.4,51) There is signiﬁcant data showing corre-
lation between SCD and 1) markers of plaque
vulnerability, such as heritable alterations of speciﬁc
matrix metalloproteinases;6) 2) markers of enhanced
thrombogenesis, such as increased D-dimer, increas-
ed apo-B, and decreased apo-A1;7) polymorphism in
platelet glycoprotein receptors;8) 3) genetic varia-
tions that predispose to vasospasm, such as varia-
tions in the vascular endothelial nitric oxide
synthetase (eNOS) system;9,10) and 4) markers of
inﬂammatory response, such as C-reactive protein
(CRP).11)
Diabetes, CAD, and risk of SCD
Cardiovascular disease is the leading cause of
death in individuals with type 2 diabetes, which
aﬀects about 15 million Americans.12) This is
compatible with the ‘‘common soil’’ hypothesis,
which postulates that both diabetes and cardiovas-
cular disease have common genetic and environ-
mental antecedents, i.e., ‘‘they spring from the same
soil.’’3,13) There is evidence that diabetes is a
signiﬁcant risk factor for SCD but not for nonfatal
MI.14) The increased risk of death and mortality rates
associated with diabetes are compounded by the fact
that many diabetic individuals are unaware that they
suﬀer from the metabolic syndrome. There is strong
evidence that the elevated risk for cardiovascular
disease starts to increase long before the onset of
clinical diabetes, conﬁrming the so-called ‘‘ticking
clock’’ hypothesis.15) The incidence of impaired
glucose tolerance and diabetes may be as high as
39% and 31%, respectively, in patients admitted
with acute MI.16) Recent studies have documented
increased inﬂammation, neovascularization, and in-
traplaque hemorrhage in human diabetic atheroscle-
rosis.17) Because of vulnerability of diabetic patients
to plaque rupture and acute MI, a question of
considerable importance is whether patients with
CAD, diabetes or prediabetes, and relatively pre-
served LV systolic function (LVEF > 35%) can
beneﬁt from primary ICD prophylaxis.
The autonomic system and enhanced suscepti-
bility to SCD
Autonomic neural inﬂuences, especially increased
adrenergic and decreased cholinergic activity, can
modulate the susceptibility to SCD following MI.
Resting heart rate has been shown to be an
independent risk factor for SCD in middle-aged
men.18) There are data showing the heritability of
heart rate variation.19) Adrenergic agonists are
known to trigger ventricular arrhythmias, and their
circulating levels have similar diurnal patterns as
SCD events.20) Genetic polymorphism of -adrener-
gic receptors have been associated with increased
susceptibility to SCD in ischemic deart disease.21)
The association between plasma nonesteriﬁed fatty
acids and SCD may be related to increased adrener-
gic tone or the eﬀect on ion channel and trans-
porters.22) Further, mental stress was found to be
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Figure 1 CAD and SCD cascade
CAD: coronary artery disease, EP: electrophysiological, ICD: implantable cardioverter deﬁbrillator, MI: myocardial infarction,
SCD: sudden cardiac death, VT/VF: ventricular tachycardia/ventricular ﬁbrillation
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associated with lateralization of mid brain activity
resulting in imbalanced activity in right and left
cardiac sympathetic nerves and increased dispersion
of repolarization, predisposing to arrhythmia.23)
Recently a third type of -adrenergic receptors, -3
adrenergic receptors were found in the human
heart.24) In both failing and post-MI myocardium,
-3 adrenergic receptors stimulation may have
protective eﬀects against -1 and -2 catecholami-
nergic stimulation.25) This makes -3 adrenergic
receptors a very attractive target for pharmacologic
therapy of cardiac arrhythmias related to cardiac
sympathetic nerve stimulation.
Cardiac gene mutations and enhanced suscep-
tibility to SCD
There is compelling evidence that a genetic
mechanism may increase a patient susceptibility to
SCD following MI. Subtle genetic variations such as
single nucleotide polymorphisms can inﬂuence the
phenotypic expression of low penetrance ion channel
mutations and increased the propensity to VA and
SCD.26) One clue of the role that genetic factors may
play in SCD has been evidence of ‘‘family cluster-
ing’’ of SCD victims. Population studies have
reported that familial clustering of SCD events is
an important independent factor in multifactorial
analyses of SCD risk. This may be related to shared
environmental or genetically transmittable abnor-
malities. Evidence favoring a focus on genetic
factors was presented in epidemiologic studies that
suggested not only that familial risks for SCD appear
substantial, but that they are statistically distinct and
separable from familial risks of MI.27–30) In one
study parental history of SCD increased the relative
risk of SCD to 1.8 after adjustment for conventional
CAD risk factors, but it did not elevate the risk for
deaths coded as non-sudden. In a small subset in
which there was a history of both maternal and
paternal SCD events, the relative risk for SCD in
oﬀspring was up to 9.4.28)
Further, the role of modiﬁer genes (gene-gene
interaction) is beginning to be appreciated. Modiﬁer
genes are genes that are not involved in the genesis
of the disease but modify the severity of the
phenotypic expression. The ﬁnal phenotype is the
result of interactions among causal genes, modiﬁer
genes, and environmental factors. Identiﬁcation
of modiﬁer genes will complement the results of
studies of causative genes and could enhance
genetic-based diagnosis, risk stratiﬁcation, and im-
plementation of preventive and therapeutic measures
of SCD.31)
Post-MI remodeling and SCD
Patients who suﬀer from a nonfatal MI as well as
those who survive SCD in the setting of acute MI
later undergo post-MI remodeling. Ventricular re-
modeling is the process by which ventricular size,
shape and function are regulated by mechanical,
neurohormonal, and genetic factors.32–34) Remodel-
ing may be physiological and adaptive during
normal growth or pathological due to MI, cardiomy-
opathy, hypertension, or valvular heart disease. Post-
MI remodeling is a complex time-dependent process
that involves structural, biochemical, neurohormonal
and electrophysiologic alterations. The acute loss of
myocardium results in an abrupt increase in loading
conditions that induces a unique pattern of remodel-
ing involving the infarcted border zone and remote
noninfarcted myocardium.35) Post-MI remodeling is
associated with time-dependent dilatation, distortion
of ventricular shape, and hypertrophy of the non-
infarcted myocardium. Following a variable period
of compensatory hypertrophy, deterioration of con-
tractile function may develop resulting in congestive
heart failure.
In recent years the understanding of the signal
transduction pathways for cardiac remodeling in the
post-MI heart36,37) has provided opportunities for
novel therapeutic interventions. Figure 2 illustrates a
proposed scheme for post-MI signaling pathways.31)
Many of these pathways were shown to be activated
either in response to ischemia/reperfusion stimuli or
to a stretch stimulus using diﬀerent experimental
models and sometimes non-cardiac cell systems.
However, cell membrane receptors and intracellular
signaling proteins are highly conserved between
mammalian species and the triggering events for
cellular hypertrophy in humans are likely to resemble
closely those in the various animal models used. The
diagram shows that a cascade of successive trans-
duction steps allows signal enhancement and diver-
siﬁcation at branching points and thus permits
combinatorial interactions between multiple path-
ways. Although multiple signaling pathways may act
in synergistic, antagonistic, or permissive way some
key pathways may play a dominant role. There is
a plethora of experimental and clinical evidence
showing that the renin-angiotensin system (RAS) and
the -adrenergic system play major roles in post-MI
remodeling.34) This explains the beneﬁcial role that
ACE inhibitors, AT-1 receptor antagonists, and -
blockers in the post-MI period. More recently, other
signaling pathways, for example, the calcineurin
pathway38) and the Janus kinase/signal transducer
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and activator of transcription (JAK-STAT)39) signal-
ing pathway were also found to play a signiﬁcant role
in post-MI remodeling. Pharmaceutical agents that
can block these pathways may provide new ther-
apeutic modalities in the post-MI period.
Post-MI remodeling and electrophysiological
vulnerability
A key electrophysiologic alteration in post-MI
remodeled heart is down regulation of Kþ gene
expression and Kþ currents resulting in spatially
heterogeneous prolongation of action potential du-
ration and increased dispersion of refractoriness.40)
For many years the observation was made that
cardiac hypertrophy from whatever cause is consis-
tently associated with down regulation of Kþ
channel genes and Kþ currents. However, recent
studies have shown that, in the post-MI heart, this
down regulation occurs early and may be dissociated
from the slower time course of post-MI remodeled
hypertrophy.40) It is therefore not surprising that the
post-MI heart is more sensitive to hypokalemia and
the proarrhythmic eﬀects of drugs that depress Kþ
currents, especially Ikr blockers. Some pharmaco-
logical interventions that have been shown to reduce
the incidence of SCD in post-MI patients, like
magnesium41) and spironolactone42) may act by
countering the eﬀects of low Kþ.
SCD and systolic dysfunction
Although the exact mechanisms involved in the
strong correlation between decreased left ventricu-
lar (LV) systolic function and increased incidence
of SCD are not clearly deﬁned, it is now
recognized that one way to combat SCD following
MI is to try to halt or improve the deterioration in
LV function. The mechanism(s) for the transition
from compensated to decompensated heart failure
is under intensive investigation and it is clear that
multiple factors are involved.43) The role of
continuous loss of cardiomyocytes to apoptosis in
the noninfarcted myocardium; the negative conse-
quences of remodeling of the interstitial matrix;
the downregulation of the -adrenergic receptor-G
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Figure 2 Post-MI signaling pathways
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protein-adenylyl cyclase pathway; the downregula-
tion of the L-type calcium current, and the
alterations in calcium regulated excitation-contrac-
tion coupling are some of the major mechanisms
involved. Recent years have seen signiﬁcant ad-
vances in the treatment of ventricular systolic
dysfunction and heart failure. The therapeutic
armamentarium includes not only pharmacological
agents, but also electrical and surgical devices.
Besides the cornerstone drugs for heart failure like
digoxin, diuretics, ACE inhibitors, and -blockers,
newer agents like the aldosterone receptor antag-
onist spironolactone, the endothelin antagonist
bosentan, the vasopeptidase inhibitor omapatrilat,
and the brain natriuretic peptide (BNP) neseritide
have been investigated in multicenter trials with
varying results.44) BNP level was shown to be a
strong predictor of SCD in patients with chronic
heart failure.45) On the other hand, electrical
devices like biventricular pacing in selected groups
of patients can improve LVEF and mortality.46)
Further, surgical procedures like passive external
support have been shown in experimental studies
to reverse remodeling with reduced systolic wall
stress and improved adrenergic signaling.47) The
success of the LV assist devices48) has shown that
even in an advanced stage of heart failure, the
remodeling process could be reversed with signiﬁ-
cant improvement of ventricular function. Finally,
clinical research has demonstrated that gene trans-
fer is a potential therapeutic option to restore
diseased cardiomyocytes and rescue the failing
heart.49)
Risk stratiﬁcation of SCD in the post-MI period
(Table)
In 2005, the Centers for Medicare and Medicaid
Services (CMS) approved primary implantable car-
diac cardioverter deﬁbrillator (ICD) for patients in
the post-MI period who have LVEF of 35% and New
York Heart Association (NYHA) class II or III heart
failure.50) These criteria were based on data from
MADIT II51) and SCD-HeFT.52)
Implantation is approved only after 40 days or
more have elapsed from the time of MI, on the basis
of data from DINAMIT.53) One area of uncertainty
of these criteria is the unreliability of LVEF
measurements as well as evolution of LVEF over
time and the way in which this inﬂuences risk.54)
There is general consensus that there is a need for
more robust risk stratiﬁcation of SCD beyond LVEF.
All completed SCD primary ICD prophylaxis
trials addressed patients with one or more conven-
tional risk factors for SCD (Table).31) The electro-
physiological surrogates for SCD, including meas-
ures of myocardial conduction disorders, dispersion
of repolarization, and autonomic imbalance, are
based on sound scientiﬁc evidence. However, the
majority of conventional electrophysiological risk
stratiﬁers of SCD have a relatively low positive
predictive value that would preclude their wide
application as guidelines for ICD implantation in
patients known to be at risk for SCD. This is not
to mention the impracticality of their use for risk
stratiﬁcation in the general asymptomatic public. It is
Table Risk Stratiﬁcation of SCD
Electrophysiological Surrogates Functional, Biochemical, and
Genetic Surrogates
Measures of conduction disorder: Funcional Markers:
SAECG, % of scar tissue in CMR -LVEF
Measures of Dispersion of Repolarization: -NYHA Class
QT dispersion, TWA
Measures of Autonomic Nervous System: Biochemical Markers:
a) Direct: sympathetic nerve activity, 1231- -C-reactive protein
MIBG scan -Homocysteine level
b) ECG-based: HRV, Baroreceptor -Serum matrix metalloproteinase
Sensitivity, HR Turbulence, QT -BNP, etc
dynamicity
Measures of altered calcium kinetics ??? Genetic Markers ???
BNP: beta natriuretic peptide, CMR: cardiac magnetic resonance, HR: heart rate, HRV: heart rate variability,
LVEF: left ventricular ejection fraction, NYHA: New York Heart Association, SAECG: signal averaged
electrocardiogram, SCD: sudden cardiac death, TWA: T-wave alternans
Curently, LVEF  35% is the main criterion for primary ICD prophylaxis.
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not therefore surprising that the current main criteria
for SCD primary ICD prophylaxis are measures of
ventricular dysfunction, i.e., LVEF and NYHA class.
There is general consensus that these criteria may
have strong predictive value for total cardiac mortal-
ity but are not speciﬁc enough for arrhythmic
mortality. This explains the continued eﬀort to
identify additional risk factors with independent or
additive predictive power for arrhythmic death.
These may include the use of newer techniques of
nuclear magnetic resonance with contrast material to
deﬁne anatomy of the infarct55) as well as possible
future use of genetic risk proﬁling.
Conclusions
The immediate future goals for risk stratiﬁcation
and management of SCD post-MI could be summa-
rized as follows: 1. Identiﬁcation of novel clinical,
biochemical, and genetic markers for SCD and
assessment of the functional consequences of se-
quence variants identiﬁed in human genetic studies
as well as relevant environmental-genetic interac-
tions. 2. Determination of the heritability of genetic
risk factors for SCD as well as the factors involved
in ethnic-speciﬁc diﬀerences in risk of SCD. 3.
Identiﬁcation of a battery of a relatively limited
number of incrementally cumulative low-intermedi-
ate risk variants and development of a ‘‘signature’’
combination of clinical, biochemical, and genetic
markers of SCD. However, we should not be
surprised that the positive predictive value of some
of the new risk factors, similar to conventional risk
factors, will be relatively low, especially if these are
applied to large populations who are at low risk. In
fact, the true value of risk stratiﬁcation of SCD in the
future may be to identify low-risk populations who
do not warrant prophylactic intervention with ther-
apy that demonstrated eﬃcacy, e.g. the ICD. 4.
Identiﬁcation of novel pharmacological and non-
pharmacological approaches for risk modiﬁcation
and prevention of SCD. One example is the interest
in clinical prevention of SCD by n-3 polyunsaturated
fatty acids. Although this relatively new diet-heart
hypothesis that underlies this therapeutic modality is
yet to catch the attention of the clinical community
at large, several experimental and clinical evidence
point to the validity of this approach.56) 5. Wider
collaboration among diﬀerent academic and indus-
trial institutions by sharing research results as well as
resources such as clinical data, blood and other
tissues from Biorepository centers. The ultimate goal
is not only to change the current direction of
management strategy of SCD away from increased
ICD utilization, but primarily to identify novel
methods for risk stratiﬁcation, risk modiﬁcation,
and prevention of SCD that could be applied to the
general public at large.
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